Tamoxifen in Postmenopausal Women
- Emily RobinsonAffiliated withComprehensive Cancer Center of Wake Forest University and the Department of Medicine, Bowman Gray School of Medicine
- , Gretchen G. KimmickAffiliated withComprehensive Cancer Center of Wake Forest University and the Department of Medicine, Bowman Gray School of Medicine
- , Hyman B. MussAffiliated withComprehensive Cancer Center of Wake Forest University and the Department of Medicine, Bowman Gray School of Medicine
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Tamoxifen is a synthetic antiestrogen with both agonist and antagonist properties. It is believed to act primarily through binding to estrogen receptors in breast cancer cells, acting as a competitive inhibitor of estrogen. Tamoxifen has a wide range of systemic effects, possibly acting on every estrogen target tissue in the body.
Tamoxifen therapy is associated with a significant reduction in the risk of recurrence and death in postmenopausal women with early stage breast cancer. In addition, it has been shown to effectively suppress preclinical breast cancer, as evidenced by the decrease in second primary breast cancers in adjuvant trials. Tamoxifen is also the most widely used endocrine therapy for women with meta-static breast cancer.
Tamoxifen, acting predominantly as an estrogen agonist in the liver, has generally favourable effects on serum lipids in postmenopausal women. In addition, tamoxifen has been shown to preserve bone mineral density and may even decrease the risk of osteoporosis in these women.
Most patients treated with tamoxifen have minimal adverse effects. Vasomotor symptoms are the most commonly reported events. Less frequently, vaginal discharge or dryness, nausea and depression have been reported. A slight increase in thrombo-embolic events in postmenopausal women taking tamoxifen has been suggested in some adjuvant trials. Rarely, ocular toxicity and hepatotoxicity are found.
The adverse effect of primary importance is the increased incidence of endo-metrial carcinoma. Several studies indicate that almost all of the tumours are of low histological grade and stage, similar to those seen with exogenous estrogen use. The relative risk of endometrial cancer in women taking tamoxifen is about 2 to 4 times higher than for postmenopausal women not taking tamoxifen.
The benefits of tamoxifen outweigh the risks in almost all postmenopausal women with estrogen receptor-positive early stage breast cancer and in all women with metastatic breast cancer. Should tamoxifen prove to be an effective chemopreventive agent for breast cancer, the risks and benefits of treatment will have to be more carefully assessed for this setting.
- Tamoxifen in Postmenopausal Women
Drugs & Aging
Volume 8, Issue 5 , pp 329-337
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors